Grant: Engage Grants Program
University of Toronto
$25,000.00
Developing and anti-flagellin IgA microplate ELISA assay as a diagnostic tool
FY 2010-11
Summary
IgA nephropathy (IgAN), also known as Berger's disease, is the most common form of glomerular disease
throughout the world. The defining hallmark of this chronic renal syndrome is the abnormal deposition of IgA
immune complexes in the kidney glomeruli. Our previous work has shown that mice over-expressing the
tumour necrosis factor (TNF) family member BAFF (for B cell activating Factor) exhibit a phenotype that is
similar to IgAN and that patients with IgAN show evidence of increased levels of BAFF and its related
homologue, APRIL, in their blood.
One of the more controversial questions in the context of IgAN is whether the pathogenic IgA in these
patients arises from the peripheral or the mucosal compartment. Our previous work has shown that BAFF-Tg
mice exhibit an IgAN phenotype due to a dysregulation of gut immune cell homeostasis, and our study has
provided new clues to the etiology of IgAN. Indeed, we showed that IgAN patient serum exhibits elevated
levels of BAFF and the related cytokine APRIL, suggesting a direct link between these molecules and IgAN
disease etiology.
In the current engage proposal, we would like to explore if IgAN patients exhibit evidence of
anti-commensal IgA antibodies in their serum. We think that this will be a good assay for identifying patients
with a more ""mucosal"" form of the disease and may suggest alternative treatment strategies. Such a diagnostic
assay may ultimately be useful for IgAN diagnosis along with other diagnostic measures.
To accomplish this, we have teamed up with Dalenyi Biosurfaces Inc. Dalenyi has developed a novel
technology for high-throughput ELISA analysis. Using the ELISA format with Dalenyi plates, we will examine
whether IgAN patients show evidence of commensal-specific IgA antibodies.
Program
Engage Grants Program
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
412279-2010
Name nom
Gommerman, Jennifer
Department département
Immunology
Organization id
31
Institution établissement
University of Toronto
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2010
Competition year année de concours
2010
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1553
Committee name en
Ontario Internal Decision Committee
Committee name fr
Comité de décision interne pour l'Ontario
Area of application code
1201
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Life sciences (including biotechnology)
Area of application fr
Sciences de la vie (y compris biotechnologie)
Research subject code
6400
Research subject group en
Life sciences research related to human health and disease
Research subject group fr
Sciences de la vie liées à la santé publique et aux maladies humaines
Research subject en
Life sciences research related to human health and disease
Research subject fr
Sciences de la vie liées à la santé publique et aux maladies humaines
Partie
1
Nb partie
1
Application title
Developing and anti-flagellin IgA microplate ELISA assay as a diagnostic tool
Keyword
NSERC
Application summary
IgA nephropathy (IgAN), also known as Berger's disease, is the most common form of glomerular disease
throughout the world. The defining hallmark of this chronic renal syndrome is the abnormal deposition of IgA
immune complexes in the kidney glomeruli. Our previous work has shown that mice over-expressing the
tumour necrosis factor (TNF) family member BAFF (for B cell activating Factor) exhibit a phenotype that is
similar to IgAN and that patients with IgAN show evidence of increased levels of BAFF and its related
homologue, APRIL, in their blood.
One of the more controversial questions in the context of IgAN is whether the pathogenic IgA in these
patients arises from the peripheral or the mucosal compartment. Our previous work has shown that BAFF-Tg
mice exhibit an IgAN phenotype due to a dysregulation of gut immune cell homeostasis, and our study has
provided new clues to the etiology of IgAN. Indeed, we showed that IgAN patient serum exhibits elevated
levels of BAFF and the related cytokine APRIL, suggesting a direct link between these molecules and IgAN
disease etiology.
In the current engage proposal, we would like to explore if IgAN patients exhibit evidence of
anti-commensal IgA antibodies in their serum. We think that this will be a good assay for identifying patients
with a more ""mucosal"" form of the disease and may suggest alternative treatment strategies. Such a diagnostic
assay may ultimately be useful for IgAN diagnosis along with other diagnostic measures.
To accomplish this, we have teamed up with Dalenyi Biosurfaces Inc. Dalenyi has developed a novel
technology for high-throughput ELISA analysis. Using the ELISA format with Dalenyi plates, we will examine
whether IgAN patients show evidence of commensal-specific IgA antibodies.